-
Article
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
Fluoropyrimidine based therapy has modest activity in patients with metastatic renal carcinoma and inhibition of ribonucleotide reductase is synergistic in model systems. GTI-2040 is a 20-mer phosphorothioate ...
-
Chapter
Cytotoxic Chemotherapy for Metastatic Renal Cell Cancer
-
Article
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
To explore the pharmacokinetics and tolerability of AZD2171, an inhibitor of vascular endothelial growth factor receptors 1 and 2, in patients with hormone refractory prostate cancer. Twenty-six patients recei...
-
Article
Sunitinib—a new standard of care for metastatic renal cell carcinoma
-
Article
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
Background: Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of bortezomib [...
-
Article
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Purpose: Bryostatin-1 is a PKC modulator with direct anti-tumor activity and immunomodulatory properties. We combined different doses of Bryostatin-1 with IL-2 to determine effects on cli...
-
Article
Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer?
-
Article
A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer
Ranpirnase (Onconase®) is the firstribonuclease to enter cancer clinicaltrials. In prior phase II trials,responses were seen in mesothelioma andother solid tumors. This phase II trialtested ranpirnase (480 μg/m2/...
-
Article
Treatment of metastatic urothelial cancer in the post-MVAC era
The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) has become the standard of care for metastatic urothelial cancer. Its efficacy has been proven in this setting but it can be a d...
-
Article
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations
In previous phase I reports of short bolus infusion of rhizoxin, problems in assay sensitivity prevented the description of pharmacokinetic-pharmacodynamic relationships, and a pharmacologically guided approa...
-
Article
Development of Target-Based Antineoplastic Agents
The elucidation of multiple potential targets in cancer cells andthe development of multiple target-based antineoplastic agentsprovide unique challenges in clinical trial design. Many of theseagents are predic...
-
Chapter
Antiangiogenic Agents and Strategies in Renal Cell Carcinoma
Although antiangiogenesis therapy recently captured the interest of the public and the research community, Folkman first described the involvement of angiogenesis in tumor growth and metastasis in the late 196...
-
Article
In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
Purpose: To determine the in vitro effects of flavopiridol on bladder cancer cell lines, immortalized urothelial cell lines, and normal urothelial cells well characterized for defects in p53, pRb, and p16. Metho...
-
Article
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer
A total of 25 patients with metastatic renal cancer were treated on a phase II protocol with 5 days of continuous-infusion fluorodeoxyuridine (FUDR), (0.1 mg/kg daily) together with high-dose oral leucovorin (...
